Neuroprotective effects of geniposide on Alzheimer's disease pathology

Reviews in the Neurosciences

Volumn 26, Issue 4, 2015, Pages 371-383

  Liu, Weizhen ^a   Li, Guanglai ^a   Hölscher, Christian ^a,b   Li, Lin ^a  

^a SHANXI MEDICAL UNIVERSITY   (China)

^b LANCASTER UNIVERSITY   (United Kingdom)

Author keywords

Alzheimer's disease; amyloid ; geniposide; glucagon like peptide receptor; neurofibrillary tangles; neuroprotection; oxidative stress; type 2 diabetes mellitus; protein

Indexed keywords

GENIPOSIDE; GLUCAGON LIKE PEPTIDE 1 RECEPTOR; NEUROPROTECTIVE AGENT; IRIDOID;

ALZHEIMER DISEASE; AMYLOID PLAQUE; AREA UNDER THE CURVE; ARTICLE; CORPUS STRIATUM; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG EFFICACY; DRUG MECHANISM; DRUG METABOLISM; ENDOPLASMIC RETICULUM STRESS; GLUCOSE METABOLISM; HIPPOCAMPUS; HUMAN; HYPOTHALAMUS; MEMORY DISORDER; NERVE FIBER GROWTH; NEUROPROTECTION; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; TISSUE DISTRIBUTION; ANIMAL; COMPLICATION; DIABETES MELLITUS, TYPE 2; PATHOLOGY;

ALZHEIMER DISEASE; ANIMALS; DIABETES MELLITUS, TYPE 2; HUMANS; IRIDOIDS; NEUROPROTECTIVE AGENTS;

EID: 84938236564     PISSN: 03341763     EISSN: None     Source Type: Journal    
DOI: 10.1515/revneuro-2015-0005     Document Type: Article

References (139)

1. Akao, T., Kobashi, K., and Aburasa, M. (1994). Enzymic studies on the animal and intestinal bacterial metabolism of geniposide. Biol. Pharm. Bull. 17, 1573-1576.
2. Akter, K., Lanza, E.A., Martin, S.A., Myronyuk, N., Rua, M., and Raffa, R.B. (2011). Diabetes and Alzheimers disease: shared pathology and treatment? Br. J. Clin. Pharmacol. 71, 365-376.
3. Aloe, L., Rocco, M.L., Branching, P., and Mani, L. (2012). Nerve growth factor: from the early discoveries to the potential clinical use. J. Transl. Med. 10, 239.
4. Antero, S., Anu, K., Tiina, S., Kai, K., and Johanna, O. (2009). ER stress in Alzheimers disease: a novel neuronal trigger for inflammation and Alzheimers pathology. J. Neuroinflamm. 6, 41.
5. Avila, J., Lucas, J.J., Perez, M., and Hernandez, F. (2004). Role of τ protein in both physiological and pathological conditions. Physiol. Rev. 84, 361-384.
6. Banhegyi, G., Mandl, J., and Csala, M. (2008). Redox-based endoplasmic reticulum dysfunction in neurological diseases. J. Neurochem. 107, 20-34.
7. Biessels, G.J., De Leeuw, F.E., Lindeboom, J., Barkhof, F., and Scheltens, P. (2006). Increased cortical atrophy in patients with Alzheimers disease and type 2 diabetes mellitus. J. Neurol. Neurosurg. Psychiatr. 77, 304-307.
8. Broca, C., Quoyer, J., Costes, S., Linck, N., Varrault, A., Deffayet, P.M., Bockaert, J., Dalle, S., and Bertrand, G. (2009). β-Arrestin 1 is required for PAC1 receptor-mediated potentiation of long-lasting ERK1/2 activation by glucose in pancreatic β-cells. J. Biol. Chem. 284, 4332-4342.
9. Burmeister, M.A., Ferre, T., Ayala, J.E., King, E.M., Holt, R.M., and Ayala, J.E. (2012). Acute activation of central GLP-1 receptors enhances hepatic insulin action and insulin secretion in high-fat-fed, insulin resistant mice. Am. J. Physiol. Endocrinol. Metab. 302, E334-E343.
10. Cattaneo, A. and Calissano, P. (2012). Nerve growth factor and Alzheimers disease: new facts for an old hypothesis. Mol. Neurobiol. 46, 588-604.
11. Chen, C., Han, F., Zhang, Y., Lu, J., and Shi, Y. (2008). Simultaneous determination of geniposide and its metabolites genipin and genipinine in culture of Aspergillus Niger by HPLC. Biomed. Chromatogr. 22, 753-757.
12. Chen, Q.C., Zhang, W.Y., Youn, U., Kim, H., Lee, I., Jung, H.J., Na, M., Min, B.S., and Bae, K. (2009). Iridoid glycosides from Gardeniae fructus for treatment of ankle sprain. Phytochemistry 70, 779-784.
13. Chen, Q.C., Zhang, W.Y., Kim, H., Lee, I.S., Ding, Y., Youn, U.J., Lee, S.M., Na, M., Min, B.S., and Bae, K. (2010). Effects of Gardeniae fructus extract and geniposide on promoting ligament cell proliferation and collagen synthesis. Phytother. Res. 24, S1-S5.
14. Chou, C.C., Pan, S.L., Teng, C.M., and Guh, J.H. (2003). Pharmacological evaluation of several major ingredients of Chinese herbal medicines in human hepatoma Hep3B cells. Eur. J. Pharm. Sci. 19, 403-412.
15. Ciron, C., Lengacher, S., Dusonchet, J., Aebischer, P., and Schneider, B.L. (2012). Sustained expression of PGC-1α in the rat nigrostriatal system selectively impairs dopaminergic function. Hum. Mol. Genet. 21, 1861-1876.
16. Corbett, A., Pickett, J., Burns, A., Corcoran, J., Dunnett, S.B., Edison, P., Hagan, J.J., Holmes, C., Jones, E., Katona, C., et al. (2012). Drug repositioning for Alzheimers disease. Nat. Rev. Drug Discov. 11, 833-846.
17. Dinamarca, M.C., Arrazola, M., Toledo, E., Cerpa, W.F., Hancke, J., and Inestrosa, N.C. (2008). Release of acetylcholinesterase (AChE) from β-amyloid plaques assemblies improves the spatial memory impairments in APP-transgenic mice. Chem. Biol. Interact. 175, 142-149.
18. Drubin, D.G. and Kirschner, M.W. (1986). τ protein function in living cells. J. Cell Biol. 103, 2739-2746.
19. Eldar-Finkelman, H., Schreyer, S.A., Shinohara, M.M., LeBoeuf, R.C., and Krebs, E.G. (1999). Increased glycogen synthase kinase-3 activity in diabetes- and obesity-prone C57BL/6J mice. Diabetes 48, 1662-1666.
20. Endres, K. and Reinhardt, S. (2013). ER-stress in Alzheimers disease: turning the scale? Am. J. Neurodegener. Dis. 2, 247-265.
21. Fagone, P. and Jackowski, S. (2009). Membrane phospholipid synthesis and endoplasmic reticulum function. J. Lipid Res. 50, S311-S316.
22. Fakhoury, M. (2015). Role of immunity and inflammation in the pathophysiology of neurodegenerative diseases. Neurodegener. Dis. Epub ahead of print.
23. Fang, F., Lue, L.F., Yan, S., Xu, H., Luddy, J.S., Chen, D., Walker, D.G., Stern, D.M., Schmidt, A.M., Chen, J.X., et al. (2010). RAGEdependent signaling in microglia contributes to neuroinflammation, Aβ accumulation, and impaired learning/memory in a mouse model of Alzheimers disease. FASEB J. 24, 1043-1055.
24. Flaherty, D.B., Soria, J.P., and Tomasiewicz, H.G. (2000). Wood JG. Phosphorylation of human τ protein by microtubule-associated kinases: GSK3β and cdk5 are key participants. J. Neurosci. Res. 62, 463-472.
25. Frost, B., Gotz, J., and Feany, M.B. (2015). Connecting the dots between τ dysfunction and neurodegeneration. Trends Cell Biol. 25, 46-53.
26. Galvez, M., Martin-Cordero, C., and Ayuso, M.J. (2005). Iridoids as DNA topoisomerase I poisons. J. Enzyme Inhib. Med. Chem. 20, 389-392.
27. Gao, C., Holscher, C., Liu, Y., and Li, L. (2011). GSK3: a key target for the development of novel treatments for type 2 diabetes mellitus and Alzheimer disease. Rev. Neurosci. 23, 1-11.
28. Gao, C., Liu, Y., Jiang, Y., Ding, J., and Li, L. (2014). Geniposide ameliorates learning memory deficits, reduces τ phosphorylation and decreases apoptosis via GSK3β pathway in streptozotocin-induced Alzheimer rat model. Brain Pathol. 24, 261-269.
29. Godoy, J.A., Rios, J.A., Zolezzi, J.M., Braidy, N., and Inestrosa, N.C. (2014). Signaling pathway cross talk in Alzheimers disease. Cell Commun. Signal. 12, 23.
30. Gong, N., Fan, H., Ma, A.N., Xiao, Q., and Wang, Y.X. (2014). Geniposide and its iridoid analogs exhibit antinociception by acting at the spinal GLP-1 receptors. Neuropharmacology 84, 31-45.
31. Gotz, J., Ittner, A., and Ittner, L.M. (2012). τ-targeted treatment strategies in Alzheimers disease. Br. J. Pharmacol. 165, 1246-1259.
32. Green, B.D., Gault, V.A., Flatt, P.R., Harriott, P., Greer, B., and OHarte, F.P. (2004). Comparative effects of GLP-1 and GIP on cAMP production, insulin secretion, and in vivo antidiabetic actions following substitution of Ala8/Ala2 with 2-aminobutyric acid. Arch. Biochem. Biophys. 428, 136-143.
33. Grundke-Iqbal, I., Iqbal, K., Quinlan, M., Tung, Y.C., and Zaidi, M.S. (1986). Wisniewski HM. Microtubule-associated protein τ. A component of Alzheimer paired helical filaments. J. Biol. Chem. 261, 6084-6089.
34. Guo, L.X., Liu, J.H., and Xia, Z.N. (2009). Geniposide inhibits CoCl2- induced PC12 cells death via the mitochondrial pathway. Chin. Med. J. (Engl.) 122, 2886-2892.
35. Guo, L.X., Xia, Z.N., Gao, X., Yin, F., and Liu, J.H. (2012). Glucagonlike peptide 1 receptor plays a critical role in geniposideregulated insulin secretion in INS-1 cells. Acta Pharmacol. Sin. 33, 237-241.
36. Ha, K.S., Kim, K.M., Kwon, Y.G., Bai, S.K., Nam, W.D., Yoo, Y.M., Kim, P.K., Chung, H.T., Billiar, T.R., and Kim, Y.M. (2003). Nitric oxide prevents 6-hydroxydopamine-induced apoptosis in PC12 cells through cGMP-dependent PI3 kinase/Akt activation. FASEB J. 17, 1036-1047.
37. Haan, M.N. (2006). Therapy insight: type 2 diabetes mellitus and the risk of late-onset Alzheimers disease. Nat. Clin. Pract. Neurol. 2, 159-166.
38. Habib, L.K., Lee, M.T., and Yang, J. (2010). Inhibitors of catalaseamyloid interactions protect cells from β-amyloid-induced oxidative stress and toxicity. J. Biol. Chem. 285, 38933-38943.
39. Han, H., Yang, L., Xu, Y., Ding, Y., Annie Bligh, S.W., Zhang, T., and Wang. Z.T. (2011). Identification of metabolites of geniposide in rat urine using ultra-performance liquid chromatography combined with electrospray ionization quadrupole time-of-flight tandem mass spectrometry. Rapid Commun. Mass Spectrom. 25, 3339-3350.
40. Hartikka, J. and Hefti, F. (1988). Comparison of nerve growth factors effects on development of septum, striatum, and nucleus basalis cholinergic neurons in vitro. J. Neurosci. Res. 21, 352-364.
41. Hashiguchi, M. and Hashiguchi, T. (2013). Kinase-kinase interaction and modulation of τ phosphorylation. Int. Rev. Cell. Mol. Biol. 300, 121-160.
42. Heneka, M.T., Kummer, M.P., and Latz, E. (2014). Innate immune activation in neurodegenerative disease. Nat. Rev. Immunol. 14, 463-477.
43. Hollingworth, P., Harold, D., Jones, L., Owen, M.J., and Williams, J. (2011). Alzheimers disease genetics: current knowledge and future challenges. Int. J. Geriatr. Psychiatry 26, 793-802.
44. Holscher, C. (2011). Diabetes as a risk factor for Alzheimers disease: insulin signalling impairment in the brain as an alternative model of Alzheimers disease. Biochem. Soc. Trans. 39, 891-897.
45. Holscher, C. (2014a). Central effects of GLP-1: new opportunities for treatments of neurodegenerative diseases. J. Endocrinol. 221, T31-T41.
46. Holscher, C. (2014b). Drugs developed for treatment of diabetes show protective effects in Alzheimers and Parkinsons diseases. Acta Physiol. Sin. 66, 497-510.
47. Hooper, C., Killick, R., and Lovestone, S. (2008). The GSK3 hypothesis of Alzheimers disease. J. Neurochem. 104, 1433-1439.
48. Hou, Y.C., Tsai, S.Y., Lai, P.Y., Chen, Y.S., and Chao, P.D.L. (2008). Metabolism and pharmacokinetics of genipin and geniposide in rats. Food Chem. Toxicol. 46, 2764-2769.
49. Hsu, H.Y., Yang, J.J., Lin, S.Y., and Lin, C.C. (1997). Comparisons of geniposidic acid and geniposide on antitumor and radioprotection after sublethal irradiation. Cancer Lett. 113, 31-37.
50. Huang, E.J. and Reichard, L.F. (2003). TRK receptors: roles in neuronal signal transduction. Annu. Rev. Biochem. 72, 609-642.
51. Huang, L., Wang, C., Naren, G., and Aori, G. (2013). Effect of geniposide on LPS-induced activation of TLR4-NF-κB pathway in RAW264.7 macrophage cell line. Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi 29, 1012-1014.
52. Iqbal, K., Liu, F., Gong, C.X., and Grundke-Iqbal, I. (2010). τ in Alzheimer disease and related tauopathies. Curr. Alzheimer Res. 7, 656-664.
53. Johnston, H., Boutin, H., and Allan, S.M. (2011). Assessing the contribution of inflammation in models of Alzheimers disease. Biochem. Soc. Trans. 39, 886-890.
54. Kamenetz, F., Tomita, T., Hsieh, H., Seabrook,G., Borcheit, D., Iwatsubo, T., Sisodia, S., and Malinow, R. (2003). APP processing and synaptic function. Neuron 37, 925-937.
55. Kang, E.B., Kwon, I.S., Koo, J.H., Kim, E.J., Kim, C.H., Lee, J., Yang, C.H., Lee, Y.I., Cho, I.H., and Cho, J.Y. (2013). Treadmill exercise represses neuronal cell death and inflammation during Aβ- induced ER stress by regulating unfolded protein response in aged presenilin 2 mutant mice. Apoptosis 18, 1332-1347.
56. Koo, H.J., Song, Y.S., Kim, H.J., Lee, Y.H., Hong, S.M., Kim, S.J., Kim, B.C., Jin, C., Lim, C.J., and Park, E.H. (2004). Antiinflammatory effects of genipin, an active principle of gardenia. Eur. J. Pharmacol. 495, 201-208.
57. Koo, H.J., Lim, K.H., Jung, H.J., and Park, E.H. (2006). Anti-inflammatory evaluation of gardenia extract, geniposide and genipin. J. Ethnopharmacol. 103, 496-500.
58. Kuo, W.H., Chou, F.P., Young, S.C., Chang, Y.C., and Wang, C.J. (2005). Geniposide activates GSH S-transferase by the induction of GST M1 and GST M2 subunits involving the transcription and phosphorylation of MEK-1 signaling in rat hepatocytes. Toxicol. Appl. Pharm. 208, 155-162.
59. Leclerc, E., Sturchler, E., and Vetter, S. (2010). The S100B/RAGE axis in Alzheimers disease. Cardiovasc. Psychiatry Neurol. 2010, 1-11.
60. Lee, H.P., Zhu, X., Casadesus, G., Castellani, R.J., Nunomura, A., Smith, M.A., Lee, H.G., and Perry, G. (2010). Antioxidant approaches for the treatment of Alzheimers disease. Expert Rev. Neurother. 10, 1201-1208.
61. Lee, H.Y., Lee, G.H., Lee, M.R., Kim, H.K., Kim, N.Y., Kim, S.H., Lee, Y.C., Kim, H.R., and Chae, H.J. (2013). Eucommia ulmoides Oliver extract, aucubin, and geniposide enhance lysosomal activity to regulate ER stress and hepatic lipid accumulation. PLoS One 8, e81349.
62. Li, L. and Holscher, C. (2007). Common pathological processes in Alzheimer disease and type 2 diabetes: a review. Brain Res. Rev. 56, 384-402.
63. Li, Y., Duffy, K.B., Ottinger, M.A., Ray, B., Bailey, J.A., Holloway, H.W., Tweedie, D., Perry, T., Mattson, M.P., Kapogiannis, D., et al. (2010). GLP-1 receptor stimulation reduces amyloid-β peptide accumulation and cytotoxicity in cellular and animal models of Alzheimers disease. J. Alzheimers Dis. 19, 1205-1219.
64. Liu, J., Zheng, X., Yin, F., Hu, Y., Guo, L., Deng, X., Chen, G., Jiajia, J., and Zhang, H. (2006). Neurotrophic property of geniposide for inducing the neuronal differentiation of PC12 cells. Int. J. Dev. Neurosci. 24, 419-424.
65. Liu, J., Yin, F., Zheng, X., Jing, J., and Hu, Y. (2007). Geniposide, a novel agonist for GLP-1 receptor, prevents PC12 cells from oxidative damage via MAP kinase pathway. Neurochem. Int. 51, 361-369.
66. Liu, J.H., Yin, F., Guo, L.X., Deng, X.H., and Hu, Y.H. (2009). Neuroprotection of geniposide against hydrogen peroxide induced PC12 cells injury: involvement of PI3 kinase signal pathway. Acta Pharmacol. Sin. 30, 159-165.
67. Liu, H.T., He, J.L., Li, W.M., Yang, Z., Wang, Y.X., Yin, J., Du, Y.G., and Yu, C. (2010). Geniposide inhibits interleukin-6 and interleukin- 8 production in lipopolysaccharide-induced human umbilical vein endothelial cells by blocking p38 and ERK1/2 signaling pathways. Inflamm. Res. 59, 451-461.
68. Liu, J., Yin, F., Xiao, H., Guo, L., and Gao, X. (2012). Glucagon-like peptide 1 receptor plays an essential role in geniposide attenuating lipotoxicity-induced β-cell apoptosis. Toxicol. In Vitro 26, 1093-1097.
69. Llorens-Martin, M., Jurado, J., Hern?dez, F., and Avila, J. (2014). GSK-3β, a pivotal kinase in Alzheimer disease. Front. Mol. Neurosci. 7, 46.
70. Lue, L.F., Walker, D.G., Brachova, L., Beach, T.G., Rogers, J., Schmidt, A.M., Stem, D.M., and Yan, S.D. (2001). Involvement of microglial receptor for advanced glycation end products (RAGE) in Alzheimers disease: identification of a cellular activation mechanism. Exp. Neurol. 171, 29-45.
71. Lv, C., Liu, X., Liu, H., Chen, T., and Zhang, W. (2014). Geniposide attenuates mitochondrial dysfunction and memory deficits in APP/PS1 transgenic mice. Curr. Alzheimer Res. 11, 580-587.
72. Lv, C., Wang, L., Liu, X., Yan, S., Yan, S.S., Wang, Y., and Zhang, W. (2015). Multi-faced neuroprotective effects of geniposide depending on the RAGE-mediated signaling in an Alzheimer mouse model. Neuropharmacology 89, 175-184.
73. Ma, T., Huang, C., Zong, G., Zha, D., Meng, X., Li, J., and Tang, W. (2011). Hepatoprotective effects of geniposide in a rat model of nonalcoholic steatohepatitis. J. Pharm. Pharmacol. 63, 587-593.
74. Ma, T., Tan, M., Yu, J., and Tan, L. (2014). Resveratrol as a therapeutic agent for Alzheimers disease. Biomed. Res. Int. 2014, 350516.
75. Mathis, C.A., Lopresti, B.J., and Klunk, W.E. (2007). Impact of amyloid imaging on drug development in Alzheimers disease. Nucl. Med. Biol. 34, 809-22.
76. Matsumi, Y., Kenzo, C., and Keiko, S. (2008). Neuro2a cell death induced by 6-hydroxydopamine is attenuated by genipin. J. Health Sci. 54, 638-644.
77. McClean, P.L., Parthsarathy, V., Faivre, E., and Holscher, C. (2011). The diabetes drug liraglutide prevents degenerative processes in a mouse model of Alzheimers disease. J. Neurosci. 31, 6587-6594.
78. McClean, P.L. and Holscher, C. (2014a). Liraglutide can reverse memory impairment, synaptic loss and reduce plaque load in aged APP/PS1 mice, a model of Alzheimer s disease. Neuropharmacol. 76, 57-67.
79. McClean, P.L. and Holscher, C. (2014b). Lixisenatide, a drug developed to treat type 2 diabetes, shows neuroprotective effects in a mouse model of Alzheimer s disease. Neuropharmacol. 86, 241-258.
80. McGeer, P.L., Itagaki, S., Boyes, B.E., and McGeer, E.G. (1988). Reactive microglia are positive for HLA-DR in the substantia nigra of Parkinsons and Alzheimers disease brains. Neurology 38, 1285-1291.
81. Meares, G.P., Mines, M.A., Beurel, E., Eom, T.Y., Song, L., Zmijewska, A.A., and Jope, R.S. (2011). Glycogen synthase kinse-3 regulates endoplasmic reticulum (ER) stress-induced CHOP expression in neuronal cells. Exp. Cell Res. 317, 1621-1628.
82. Meda, L., Cassatella, M.A., Szendrei, G.I., Otvos, L. Jr., Baron, P., Villalba, M., Ferrari, D., and Rossi, F. (1995). Activation of microglial cells by β-amyloid protein and interferon- γ. Nature 374, 647-650.
83. Medina, M. and Avila, J. (2014). New perspectives on the role of τ in Alzheimers disease. Implications for therapy. Biochem. Pharmacol. 88, 540-547.
84. Morris, G.P., Clark, I.A., and Vissel, B. (2014). Inconsistencies and controversies surrounding the amyloid hypothesis of Alzheimers disease. Acta Neuropathol. Commun. 2, 135.
85. Murakami, T., Hino, S.I., Saito, A., and Imaizumi, K. (2007). Endoplasmic reticulum stress response in dendrites of cultured primary neurons. Neuroscience 146, 1-8.
86. Nelson, T.J. and Alkon, D.I. (2005). Insulin and cholesterol pathways in neuronal function, memory and neurodegeneration. Biochem. Soc. Trans. 33, 1033-1036.
87. Pan, L., Zhou, J., Zhu, H., Wang, W., Zhang, M., Tian, X., Lu, J., and Zeng, M. (2014). Study on integrated pharmacokinetics of gardenia acid and geniposide: time-antioxidant efficacy after oral administration of Huanglian-Zhizi couplet medicine from Huang-Lian-Jie-Du-Tang in MCAO rats. Am. J. Chin. Med. 42, 393-407.
88. Parihar, M.S. and Brewer, G.J. (2010). Amyloid-β as a modulator of synaptic plasticity. J. Alzheimers Dis. 22, 741-763.
89. Patapoutian, A. and Reichardt, L.F. (2001). Trk receptors: mediators of neurotrophin action. Curr. Opin. Neurobiol. 11, 272-280.
90. Perry, T. and Greig, N.H. (2005). Enhancing central nervous system endogenous GLP-1 receptor pathways for intervention in Alzheimers disease. Curr. Alzheimer Res. 2, 377-385.
91. Perry, T., Lahiri, D.K., Chen, D., Zhou, J., Shaw, K.T., Egan, J.M., and Greig, N.H. (2002). A novel neurotrophic property of glucagonlike peptide 1: a promoter of nerve growth factor-mediated differentiation in PC12 cells. J. Pharmacol. Exp. Ther. 300, 958-966.
92. Perry, T., Lahiri, D.K., Sambamurti, K., Chen, D., Mattson, M.P., Egan, J.M., and Greig, N.H. (2003). Glucagon-like peptide-1 decreases endogenous amyloid β peptide (Aβ) levels and protects hippocampal neurons from death induced by Aβ and iron. J. Neurosci. Res. 72, 603-612.
93. Piaceri, I., Rinnoci, V., Bagnoli, S., Failli, Y., and Sorbi, S. (2012). Mitochondria and Alzheimers disease. J. Neurol. Sci. 322, 31-34.
94. Pimplikar, S.W. (2009). Reassessing the amyloid cascade hypothesis of Alzheimers disease. Int. J. Biochem. Cell Biol. 41, 1261-1268.
95. Raff, M.C., Whitmore, A.V., and Finn, J.T. (2002). Axonal self-destruction and neurodegeneration. Science 296, 868-871.
96. Rakez, K. and Cristian, A.L.R. (2013). Molecular mechanisms of amyloid oligomers toxicity. J. Alzheimers Dis. 33, s67-s78.
97. Ristow, M. (2004). Neurodegenerative disorders associated with diabetes mellitus. J. Mol. Med. 82, 510-529.
98. Rubio-Perez, J.M. and Morillas-Ruiz, J.M. (2012). A review: inflammatory process in Alzheimers disease, role of cytokines. Sci. World J. 2012, 756357.
99. Sabbagh, M.N., Galasko, D., Koo, E., and Thal, L.J. (2000). Amyloid-β and treatment opportunities for Alzheimers disease. J. Alzheimers Dis. 2, 231-259.
100. Salminen, A., Kauppinen, A., Hyttinen, J.M., Toropainen, E., and Kaarniranta, K. (2010). Endoplasmic reticulum stress in agerelated macular degeneration: trigger for neovascularization. Mol. Med. 16, 535-542.
101. Sammels, E., Parys, J.B., Missiaen, L., De Smedt, H., and Bultynck, G. (2010). Intracellular Ca2+ storage in health and disease: a dynamic equilibrium. Cell Calcium 47, 297-314.
102. Selkoe, D.J. (2008). Soluble oligomers of the amyloid-β protein impair synaptic plasticity and behavior. Behav. Brain Res. 192, 106-113.
103. Shao, S., Liu, Z., Yang, Y., Zhang, M., and Yu, X. (2010). SREBP-1c, Pdx-1, and GLP-1R involved in palmitate-EPA regulated glucosestimulated insulin secretion in INS-1 cells. J. Cell. Biochem. 111, 634-642.
104. Sharma, M., Jalewa, J., and Holscher, C. (2013). Neuroprotective and anti-apoptotic effects of liraglutide on SH-SY5Y cells exposed to methylglyoxal stress. J. Neurochem. 128, 459-471.
105. Song, X., Zhang, W., Wang, T., Jiang, H., Zhang, Z., Fu, Y., Yang, Z., Cao, Y., and Zhang, N. (2014). Geniposide plays an anti-inflammatory role via regulating TLR4 and downstream signaling pathways in lipopolysaccharide-induced mastitis in mice. Inflammation 37, 1588-1598.
106. Stalder, M., Phinney, A., Probst, A., Sommer, B., Staufenbiel, M., and Jucker, M. (1999). Association of microglia with amyloid plaques in brains of APP23 transgenic mice. Am. J. Pathol. 154, 1673-1684.
107. Sudduth, T.L., Schmitt, F.A., Nelson, P.T., and Wilcock, D.M. (2013). Neuroinflammatory phenotype in early Alzheimers disease. Neurobiol. Aging 34, 1051-1059.
108. Sun, Y., Feng, F., and Yu, X. (2012). Pharmacokinetics of geniposide in Zhi-Zi-Hou-Pu decoction and in different combinations of its constituent herbs. Phytother. Res. 26, 67-72.
109. Tan, C.C., Yu, J.T., Wang, H.F., Tan, M.S., Meng, X.F., Wang, C., Jiang, T., Zhu, X.C., and Tan, L. (2014). Efficacy and safety of donepezil, galantamine, rivastigmine, and memantine for the treatment of Alzheimers disease: a systematic review and meta-analysis. J. Alzheimers Dis. 41, 615-631.
110. Tanaka, M., Yamazaki, M., and Chiba, K. (2009). Neuroprotective action of genipin on tunicamycin-induced cytotoxicity in neuro2a cells. Biol. Pharm. Bull. 32, 1220-1223.
111. Terwel, D., Dewachter, I., and Van Leuven, F. (2002). Axonal transport, τ protein, and neurodegeneration in Alzheimers disease. Neuromol. Med. 2, 151-165.
112. Thinakaran, G. and Koo, E.H. (2008). Amyloid precursor protein trafficking, processing, and function. J. Biol. Chem. 283, 29615-29619.
113. Torres, M., Matamala, J.M., Duran-Aniotz, C., Cornejo, V.H., Foley, A., and Hetz, C. (2014). ER stress signaling and neurodegeneration: at the intersection between Alzheimers disease and prion-related disorders. Virus Res. DOI: 10.1016/j.virusres. 2014.12.018.
114. Ueno, K., Takeda, Y., Iwasaki, Y., and Yoshizaki, F. (2001). Simultaneous estimation of geniposide and genipin in mouse plasma using high-performance liquid chromatography. Anal. Sci. 17, 1237-1239.
115. Wang, S.W., Lai, C.Y., and Wang, C.J. (1992). Inhibitory effect of geniposide on aflatoxin B1-induced DNA repair synthesis in primary cultured rat hepatocytes. Cancer Lett. 65, 133-137.
116. Wang, X.H., Li, L., Holscher, C., Pan, Y.F., Chen, X.R., and Qi, J.S. (2010). Val8-glucagon-like peptide-1 protects against Aβ1-40- induced impairment of hippocampal late-phase long-term potentiation and spatial learning in rats. Neuroscience 170, 1239-1248.
117. Wang, J., Hou, J., Zhang, P., Li, D., Zhang, C., and Liu, J. (2012a). Geniposide reduces inflammatory responses of oxygen-glucose deprived rat microglial cells via inhibition of the TLR4 signaling pathway. Neurochem. Res. 37, 2235-2248.
118. Wang, J., Li, P.T., Du, H., Hou, J.C., Li, W.H., Pan, Y.S., and Chen, H.C. (2012b). Tong Luo Jiu Nao injection, a traditional Chinese medicinal preparation, inhibits MIP-1 expression in brain microvascular endothelial cells injured by oxygen-glucose deprivation. J. Ethnopharmacol. 141, 151-157.
119. Wang, F., Cao, J., Hao, J., and Liu, K. (2014). Pharmacokinetics, bioavailability and tissue distribution of geniposide following intravenous and peroral administration to rats. Biopharm. Drug Dispos. 35, 97-103.
120. Werner, J.G. and Altaf, S.D. (2015). Pharmacotherapy of Alzheimers disease: current and future trends. Expert Rev. Neurother. 15, 3-5.
121. Wright, J.W., Kawas, L.H., and Harding, J.W. (2014). The development of small molecule angiotensin IV analogs to treat Alzheimers and Parkinsons diseases. Prog. Neurobiol. 125C, 26-46.
122. Wu, R.G., Qiu, L., Zhang, Y., Zhang, Z.J., Luo, Y.J., and Wang, Y.Y. (2009). Microarray and proteomic characterization of molecular mechanism of geniposide in ischemia reperfusion and computer-automated estimation of the possible drug target network. Neurosci. Res. 65, S122.
123. Yamamoto, M., Miura, N., and Ohtake, N. (2000). Genipin, a metabolite derived from the herbal medicine Inchin-ko-to, and suppression of Fas-induced lethal liver apoptosis in mice. Gastroenterology 118, 380-389.
124. Yamazaki, M., Chiba, K., and Mohri, T. (1996). Neuritogenic effect of natural iridoid compounds on PC12h cells and its possible relation to signaling protein kinases. Biol. Pharm. Bull. 19, 791-795.
125. Yamazaki, M., Chiba, K., and Mohri, T. (2001a). Activation of the mitogen-activated protein kinase cascade through nitric oxide synthesis as a mechanism of neuritogenic effect of genipin in PC12h cells. J. Neurochem. 79, 45-54.
126. Yamazaki, M., Sakura, N., and Chiba, K. (2001b). Prevention of the neurotoxicity of the amyloid β protein by genipin. Biol. Pharm. Bull. 24, 1454-1455.
127. Yamazaki, M., Chiba, K., Mohri, T., and Hatanaka, H. (2004). Cyclic GMP-dependent neurite outgrowth by genipin and nerve growth factor in PC12h cells. Eur. J. Pharmacol. 488, 35-43.
128. Yamazaki, M., Chiba, K., and Mohri, T. (2006). Differences in neuritogenic response to nitric oxide in PC12 and PC12h cells. Neurosci. Lett. 393, 222-225.
129. Yamazaki, M., Chiba, K., and Yoshikawa, C. (2009). Genipin suppresses A23187-induced cytotoxicity in neuro2a cells. Biol. Pharm. Bull. 32, 1043-1046.
130. Yan, S.F., Du, Yan, S., Ramasamy, R., and Schmidt, A.M. (2009). Tempering the wrath of RAGE: an emerging therapeutic strategy against diabetic complications, neurodegeneration, and inflammation. Ann. Med. 2009, 1-15.
131. Yan, S.S., Chen, D., Yan, S., Guo, L., Du, H., and Chen, J.X. (2012). RAGE is a key cellular target for Aβ-induced perturbation in Alzheimers disease. Front. Biosci. (Schol. Ed.) 4, 240-250.
132. Ye, G., Zhu, H.Y., Zhao, H.L., Xu, B., and Huang, C.G. (2006). HPLC method for the determination and pharmacokinetic studies on geniposide in rat serum after oral administration of traditional Chinese medicinal preparation Yin-Zhi-Ku decoction. Biomed. Chromatogr. 20, 743-747.
133. Yin, F., Liu, J., Zheng, X., Guo, L., and Xiao, H. (2010a). Geniposide induces the expression of heme oxygenase-1 via PI3K/Nrf2- signaling to enhance the antioxidant capacity in primary hippocampal neurons. Biol. Pharm. Bull. 33, 1841-1846.
134. Yin, F., Liu, J.H., Zheng, X.X., and Guo, L.X. (2010b). GLP-1 receptor plays a critical role in geniposide-induced expression of heme oxygenase-1 in PC12 cells. Acta Pharmacol. Sin. 31, 540-545.
135. Yin, F., Zhang, Y., Guo, L., Kong, S., and Liu, J. (2012). Geniposide regulates insulin-degrading enzyme expression to inhibit the cytotoxicity of Aβ1-42 in cortical neurons. CNS Neurol. Disord. Drug Targets 11, 1045-1051.
136. Yu, Y., Xie, Z.L., and Gao, H. (2009). Bioactive iridoid glucosides from the fruit of Gardenia jasminoides. J. Nat. Prod. 72, 1459-1464.
137. Yu, B., Ruan, M., Cui, X.B., Guo, J.M., Xu, L., and Dong, X.P. (2013). Effect of borneol on the pharmacokinetics of geniposide in cortex, hippocampus, hypothalamus and striatum of conscious rat by simultaneous microdialysis coupled with UPLC-MS. J. Pharm. Biomed. Anal. 77, 128-132.
138. Zheng, X., Yang, D., Liu, X., Wang, N., Li, B., Cao, H., Lu, Y., Wei, G., Zhou, H., and Zheng, J. (2010). Identification of a new anti-LPS agent, geniposide from Gardenia jasminoides Ellis, and its ability of direct binding and neutralization of lipopolysaccharide in vitro and in vivo. Int. Immunopharmacol. 10, 1209-1219.
139. Zhu, J., Gao, X., Xie, W.L., Jin, Y.Z., and Sun, W.J. (2005). Effect of geniposide on serum IL-1β and TNF-α of rheumatoid arthritis rats. China J. Chin. Mat. Med. 30, 708-711.